Article

Dispersive OVD gains FDA approval

The FDA has approved a dispersive ophthalmic viscosurgical device (OVD) (Healon EndoCoat OVD, Abbott Medical Optics) for use as a surgical aid in cataract extraction and IOL implantation.

Abbott Park, IL-The FDA has approved a dispersive ophthalmic viscosurgical device (OVD) (Healon EndoCoat OVD, Abbott Medical Optics) for use as a surgical aid in cataract extraction and IOL implantation.

The OVD is injected into a patient’s eye to protect and coat the eye during surgery. It is designed to reduce trauma to the inside layer of the cornea and other surrounding tissues.

“A dispersive OVD is highly desirable at the beginning of the cataract removal process to help protect the eye from nuclear particles and ultrasonic energy,” said Roger F. Steinert, MD, the Irving H. Leopold Professor and Chair, and director of the Gavin Herbert Eye Institute, at the University of California, Irvine. “[This new dispersive viscosurgical device] is ideal for this protective barrier. It has outstanding clarity and does not require refrigeration, which reduces surgicenter storage costs and improves ease of use compared with a cold syringe.”

Dispersive OVDs are expected to account for approximately 50% of the total OVD market in 2012, according to the ophthalmic research firm Market Scope.

The product has begun to be shipped in the United States.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.